The ULTIMA Trial
EKOS Endovascular System PE Clinical Studies
Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis
for Acute Intermediate-Risk Pulmonary Embolism
Nils Kucher, MD et al. Circulation 2014; 129: 479-486
RV/LV ratio significantly improved at 24 hours.
Reduction in RV/LV ratio significantly greater at 24 hours and improved at 90 days.
No deaths or significant bleeding complications.
Systolic RV dysfunction significantly improved.
ULTIMA confirmed that a fixed-dose, ultrasound-assisted catheter-directed thrombolysis using EKOS regimen was superior to anticoagulation alone in improving RV dysfunction at 24 hours without an increase in bleeding complications.